New York, February 10, 2026, 05:11 EST — Premarket
- Abpro Holdings surged roughly 94% ahead of the bell, following a fresh ownership filing.
- Goldman Sachs entities owned 6.8% of Abpro’s common stock at the end of December, according to a Schedule 13G filing.
- Traders are eyeing if the move sticks through the cash open, following a burst of after-hours action.
Abpro Holdings, Inc shares soared roughly 94% to $2.95 early Tuesday, premarket, after a regulatory filing revealed a sizable new investor in the microcap biotech.
The filing revealed The Goldman Sachs Group and Goldman Sachs & Co. LLC held 196,537 shares—6.8% of Abpro’s common stock—as of Dec. 31. Goldman filed a Schedule 13G, the short-form disclosure investors use when their stake tops 5% but remains passive. According to the document, the shares are kept in the “ordinary course of business,” with no intent to sway company control. SEC
Abpro shares closed at $1.52 on Monday, a 1.33% gain, with volume landing near 2.77 million shares, market data show.
SEC records indicate the Schedule 13G came in on Feb. 9, with acceptance logged at 4:07 p.m. ET.
The action rolled right into after-hours, with Abpro changing hands at $2.8598 as of Monday evening—an 88% jump. Roughly 14 million shares traded after the bell, according to MarketWatch data.
Massachusetts biotech Abpro is working on multispecific antibody therapies. Last month, the company and Celltrion (South Korea) announced the U.S. FDA had greenlit their investigational new drug application for ABP-102/CT-P72. They expect to kick off a Phase 1 trial in the first half of 2026.
Abpro shares swung from $2.88 to $2.95 during Tuesday’s premarket action—those quick gaps, typical for thinly traded early sessions.
But a 13G only shows a moment in time. The filing is based on holdings as of Dec. 31—it doesn’t specify when the shares were picked up or if that stake still holds. In small-cap names, big premarket swings like these can unravel fast after the bell, as trading volume picks up.
